These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

943 related articles for article (PubMed ID: 21764753)

  • 21. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
    Calarese DA; Scanlan CN; Zwick MB; Deechongkit S; Mimura Y; Kunert R; Zhu P; Wormald MR; Stanfield RL; Roux KH; Kelly JW; Rudd PM; Dwek RA; Katinger H; Burton DR; Wilson IA
    Science; 2003 Jun; 300(5628):2065-71. PubMed ID: 12829775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural basis for germline antibody recognition of HIV-1 immunogens.
    Scharf L; West AP; Sievers SA; Chen C; Jiang S; Gao H; Gray MD; McGuire AT; Scheid JF; Nussenzweig MC; Stamatatos L; Bjorkman PJ
    Elife; 2016 Mar; 5():. PubMed ID: 26997349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.
    Li Y; O'Dell S; Wilson R; Wu X; Schmidt SD; Hogerkorp CM; Louder MK; Longo NS; Poulsen C; Guenaga J; Chakrabarti BK; Doria-Rose N; Roederer M; Connors M; Mascola JR; Wyatt RT
    J Virol; 2012 Oct; 86(20):11231-41. PubMed ID: 22875963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.
    Pancera M; Shahzad-Ul-Hussan S; Doria-Rose NA; McLellan JS; Bailer RT; Dai K; Loesgen S; Louder MK; Staupe RP; Yang Y; Zhang B; Parks R; Eudailey J; Lloyd KE; Blinn J; Alam SM; Haynes BF; Amin MN; Wang LX; Burton DR; Koff WC; Nabel GJ; Mascola JR; Bewley CA; Kwong PD
    Nat Struct Mol Biol; 2013 Jul; 20(7):804-13. PubMed ID: 23708607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germlining of the HIV-1 broadly neutralizing antibody domain m36.
    Chen W; Li W; Ying T; Wang Y; Feng Y; Dimitrov DS
    Antiviral Res; 2015 Apr; 116():62-6. PubMed ID: 25676867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.
    Gift SK; Zentner IJ; Schön A; McFadden K; Umashankara M; Rajagopal S; Contarino M; Duffy C; Courter JR; Zhang MY; Gershoni JM; Cocklin S; Dimitrov DS; Smith AB; Freire E; Chaiken IM
    Biochemistry; 2011 Apr; 50(14):2756-68. PubMed ID: 21351734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.
    Wu L; Zhou T; Yang ZY; Svehla K; O'Dell S; Louder MK; Xu L; Mascola JR; Burton DR; Hoxie JA; Doms RW; Kwong PD; Nabel GJ
    J Virol; 2009 May; 83(10):5077-86. PubMed ID: 19264769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.
    Falkowska E; Ramos A; Feng Y; Zhou T; Moquin S; Walker LM; Wu X; Seaman MS; Wrin T; Kwong PD; Wyatt RT; Mascola JR; Poignard P; Burton DR
    J Virol; 2012 Apr; 86(8):4394-403. PubMed ID: 22345481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library.
    Khan L; Kumar R; Thiruvengadam R; Parray HA; Makhdoomi MA; Kumar S; Aggarwal H; Mohata M; Hussain AW; Das R; Varadarajan R; Bhattacharya J; Vajpayee M; Murugavel KG; Solomon S; Sinha S; Luthra K
    Sci Rep; 2017 Mar; 7():45163. PubMed ID: 28332627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies.
    Pujanauski LM; Janoff EN; McCarter MD; Pelanda R; Torres RM
    Proc Natl Acad Sci U S A; 2013 Jan; 110(4):1422-7. PubMed ID: 23288906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.
    Bonsignori M; Montefiori DC; Wu X; Chen X; Hwang KK; Tsao CY; Kozink DM; Parks RJ; Tomaras GD; Crump JA; Kapiga SH; Sam NE; Kwong PD; Kepler TB; Liao HX; Mascola JR; Haynes BF
    J Virol; 2012 Apr; 86(8):4688-92. PubMed ID: 22301150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01.
    Guo D; Shi X; Arledge KC; Song D; Jiang L; Fu L; Gong X; Zhang S; Wang X; Zhang L
    J Biol Chem; 2012 Dec; 287(51):43170-9. PubMed ID: 23100255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.
    Zwick MB; Parren PW; Saphire EO; Church S; Wang M; Scott JK; Dawson PE; Wilson IA; Burton DR
    J Virol; 2003 May; 77(10):5863-76. PubMed ID: 12719580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120.
    Bagley J; Dillon PJ; Rosen C; Robinson J; Sodroski J; Marasco WA
    Mol Immunol; 1994 Oct; 31(15):1149-60. PubMed ID: 7935503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor.
    Kong L; Ju B; Chen Y; He L; Ren L; Liu J; Hong K; Su B; Wang Z; Ozorowski G; Ji X; Hua Y; Chen Y; Deller MC; Hao Y; Feng Y; Garces F; Wilson R; Dai K; O'Dell S; McKee K; Mascola JR; Ward AB; Wyatt RT; Li Y; Wilson IA; Zhu J; Shao Y
    Immunity; 2016 Apr; 44(4):939-50. PubMed ID: 27067056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site.
    Gristick HB; von Boehmer L; West AP; Schamber M; Gazumyan A; Golijanin J; Seaman MS; Fätkenheuer G; Klein F; Nussenzweig MC; Bjorkman PJ
    Nat Struct Mol Biol; 2016 Oct; 23(10):906-915. PubMed ID: 27617431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
    Kwong PD; Wyatt R; Robinson J; Sweet RW; Sodroski J; Hendrickson WA
    Nature; 1998 Jun; 393(6686):648-59. PubMed ID: 9641677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.
    Joyce MG; Kanekiyo M; Xu L; Biertümpfel C; Boyington JC; Moquin S; Shi W; Wu X; Yang Y; Yang ZY; Zhang B; Zheng A; Zhou T; Zhu J; Mascola JR; Kwong PD; Nabel GJ
    J Virol; 2013 Feb; 87(4):2294-306. PubMed ID: 23236069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.